

Renin-Angiotensin-Aldosterone System Pathways in Hypertension and Obese Adolescents

Aadya Shrokowa*

Department of Neurology, University of Bergamo, 24129 Bergamo, Italy

Abstract

The Renin-Angiotensin-Aldosterone System (RAAS) plays a pivotal role in regulating blood pressure and fluid balance, with both classical and alternative pathways contributing to its physiological effects. This review examines the involvement of RAAS pathways in the pathogenesis of hypertension and obesity in adolescents. Classical RAAS activation involves the conversion of angiotensinogen to Angiotensin II (Ang II), leading to vasoconstriction and aldosterone release, while alternative pathways, such as the Angiotensin-Converting Enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor axis, counterbalance these effects by promoting vasodilation and natriuresis. In obese adolescents, dysregulation of RAAS pathways contributes to hypertension through mechanisms including adipocyte-derived angiotensinogen, insulin resistance and sympathetic nervous system activation. Understanding the interplay between classical and alternative RAAS pathways is crucial for developing targeted interventions to manage hypertension and obesity-related complications in adolescents.

Keywords: Renin-angiotensin-aldosterone system • Obesity • Vasodilation • RAAS pathways

Introduction

The Renin-Angiotensin-Aldosterone System (RAAS) is a key regulatory pathway involved in blood pressure regulation and fluid balance. Its dysregulation is implicated in the pathogenesis of hypertension, a prevalent cardiovascular disorder with significant health implications, particularly in adolescents. Additionally, obesity, which has reached epidemic proportions worldwide, is closely associated with hypertension and further exacerbates cardiovascular risks in this population. Understanding the intricate interplay between classical and alternative pathways of the RAAS in the context of hypertension and obesity in adolescents is essential for developing effective therapeutic strategies to mitigate cardiovascular complications. The classical pathway of the RAAS involves the conversion of angiotensinogen to Angiotensin II (Ang II) via the actions of renin and Angiotensin-Converting Enzyme (ACE). Ang II exerts vasoconstrictive effects and stimulates aldosterone release, leading to sodium retention and increased blood pressure. In obese adolescents, adipocyte-derived angiotensinogen contributes to RAAS activation, perpetuating hypertension and promoting cardiovascular remodelling. Furthermore, insulin resistance, a hallmark of obesity, enhances RAAS activity, exacerbating hypertension through mechanisms involving oxidative stress and endothelial dysfunction [1,2].

Literature Review

Emerging evidence highlights the role of alternative RAAS pathways, including the Angiotensin-Converting Enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor axis, in counterbalancing the effects of the classical pathway. ACE2 cleaves Ang II to generate angiotensin-(1-7), which promotes vasodilation and natriuresis through Mas receptor activation. Dysregulation of the ACE2/

angiotensin-(1-7)/Mas receptor axis has been implicated in the pathogenesis of hypertension and obesity-related complications in adolescents. Understanding the balance between classical and alternative RAAS pathways is crucial for elucidating the pathophysiology of hypertension and obesity and identifying novel therapeutic targets. This literature review aims to synthesize current knowledge on the involvement of RAAS pathways in hypertension and obesity in adolescents, with a focus on the underlying mechanisms and potential therapeutic implications. By elucidating the complex interplay between RAAS activation, hypertension and obesity, this review provides insights into the development of targeted interventions to mitigate cardiovascular risks in this vulnerable population [3].

Recent research has shed light on the intricate mechanisms underlying RAAS dysregulation in hypertension and obesity among adolescents. Studies have demonstrated that RAAS activation contributes not only to elevated blood pressure but also to the development of target organ damage, including cardiac hypertrophy, vascular remodelling and renal dysfunction. Moreover, the interaction between RAAS and other signalling pathways, such as the sympathetic nervous system and inflammatory cascades, further exacerbates cardiovascular risks in adolescents with hypertension and obesity. Interventions targeting RAAS pathways have emerged as promising strategies for managing hypertension and obesity-related complications in adolescents. Pharmacological agents that block RAAS components, such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and mineralocorticoid receptor antagonists, have demonstrated efficacy in reducing blood pressure and improving cardiovascular outcomes in this population. Furthermore, lifestyle modifications, including weight management, physical activity and dietary sodium restriction, have been shown to attenuate RAAS activation and mitigate hypertension in obese adolescents. However, several challenges remain in translating these findings into clinical practice. Identifying biomarkers of RAAS dysregulation and personalized approaches to treatment are essential for optimizing therapeutic outcomes and minimizing adverse effects. Moreover, long-term studies are needed to assess the efficacy and safety of RAAS-targeted interventions in adolescents and elucidate their impact on cardiovascular morbidity and mortality [4].

Discussion

The discussion of the Renin-Angiotensin-Aldosterone System (RAAS) pathways in the context of hypertension and obesity in adolescents encompasses a multifaceted exploration of the underlying mechanisms, therapeutic implications, challenges and future directions. Firstly, the

*Address for Correspondence: Aadya Shrokowa, Department of Neurology, University of Bergamo, 24129 Bergamo, Italy, E-mail: aadyashrokowa@gmail.com

Copyright: © 2024 Shrokowa A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 03 February, 2024, Manuscript No. jhoa-24-129440; **Editor Assigned:** 05 February, 2024, PreQC No. P-129440; **Reviewed:** 17 February, 2024, QC No. Q-129440; **Revised:** 22 February, 2024, Manuscript No. R-129440; **Published:** 29 February, 2024, DOI: 10.37421/2167-1095.2024.13.444

discussion delves into the intricate interplay between classical and alternative RAAS pathways. Classical RAAS activation, characterized by angiotensin II-mediated vasoconstriction and aldosterone-induced sodium retention, contributes to elevated blood pressure in hypertensive and obese adolescents. Conversely, alternative RAAS pathways, such as the ACE2/angiotensin-(1-7)/Mas receptor axis exert vasodilatory and natriuretic effects, serving as a counterbalance to mitigate hypertension and its associated cardiovascular complications. Moreover, the discussion highlights the role of RAAS dysregulation in promoting target organ damage, including cardiac hypertrophy, vascular remodelling and renal dysfunction. Understanding the pathophysiological mechanisms underlying RAAS-mediated cardiovascular complications is crucial for developing targeted interventions to prevent disease progression and improve long-term outcomes in adolescents [5].

The discussion also addresses the therapeutic implications of targeting RAAS pathways in the management of hypertension and obesity-related complications in adolescents. Pharmacological agents that modulate RAAS activity, such as ACE inhibitors, ARBs and mineralocorticoid receptor antagonists, have demonstrated efficacy in reducing blood pressure and improving cardiovascular outcomes. Lifestyle modifications, including weight management and dietary sodium restriction, complement pharmacological interventions by attenuating RAAS activation and mitigating hypertension in obese adolescents. However, the discussion also acknowledges the challenges associated with translating RAAS-targeted interventions into clinical practice. These challenges include identifying biomarkers of RAAS dysregulation, optimizing treatment strategies based on individual patient characteristics and assessing the long-term efficacy and safety of RAAS-targeted therapies in adolescents [6].

Conclusion

In conclusion, the discussion underscores the pivotal role of the RAAS in the pathogenesis of hypertension and obesity-related cardiovascular complications in adolescents. By elucidating the complex interplay between classical and alternative RAAS pathways, this review provides insights into the development of targeted interventions to mitigate cardiovascular risks in this vulnerable population. Moving forward, further research is warranted to unravel the underlying mechanisms of RAAS dysregulation, identify novel therapeutic targets and optimize treatment strategies for managing hypertension and obesity-related complications in adolescents. By addressing

these challenges and embracing interdisciplinary approaches, we can advance our understanding of RAAS-mediated cardiovascular disease and improve the health outcomes of adolescents worldwide.

Acknowledgment

None.

Conflict of Interest

No conflict of interest.

References

1. Cruz-López, Edwyn O., Dien Ye, Congqing Wu and Hong S. Lu, et al. "Angiotensinogen suppression: A new tool to treat cardiovascular and renal disease." *Hypertension* 79 (2022): 2115-2126.
2. Vargas, Rafael Antonio Vargas, Jesús María Varela Millán and Esperanza Fajardo Bonilla. "Renin-angiotensin system: Basic and clinical aspects-a general perspective." *Endocrinol Diabetes Nutr* 69 (2022): 52-62.
3. Martyniak, Adrian and Przemyslaw J. Tomasik. "A new perspective on the renin-angiotensin system." *Diagnostics* 13 (2022): 16.
4. Thomas, Walter G. and Frederick AO Mendelsohn. "Angiotensin receptors: Form and function and distribution." *Int J Biochem Cell Biol* 35 (2003): 774-779.
5. Chai, S. Y., R. Fernando, G. Peck and S. Y. Ye, et al. "The angiotensin IV/AT4 receptor." *Cell Mol Life Sci* 61 (2004): 2728-2737.
6. Molina-Van den Bosch, M., C. Jacobs-Cachá, A. Vergara and D. Serón, et al. "The renin-angiotensin system and the brain." *Hipertens Riesgo Vasc* 38 (2021): 125-132.

How to cite this article: Shrokowa, Aadya. "Renin-Angiotensin-Aldosterone System Pathways in Hypertension and Obese Adolescents." *J Hypertens* 13 (2024): 444.